Work Here?
Aadi Bioscience
Work Here?
Develops mTOR-targeted therapeutics for rare diseases
Aadi Bioscience
Work Here?
Develops mTOR-targeted therapeutics for rare diseases
Overview
Aadi Bioscience develops and commercializes medicines that target the mTOR pathway, focusing on rare and difficult-to-treat diseases. Its lead product, nab-sirolimus (ABI 009), is sirolimus bound to albumin nanoparticles designed for injectable use to treat advanced malignant PEComa, a rare cancer, and is being explored for other conditions such as treatment-resistant epilepsy. The drug works by inhibiting the mTOR signaling pathway, which helps control cell growth and metabolism. The company differentiates itself by concentrating on niche, high-need markets and pursuing orphan drug designations to gain market exclusivity, along with a specialized formulation that aims to improve delivery. Its goal is to advance clinical development, obtain regulatory approval, and bring novel therapies to patients underserved by current treatments, while potentially partnering with larger pharma companies for commercialization and expanding its indications.
About Aadi Bioscience
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Post IPO Equity
Headquarters
Los Angeles, California
Founded
2011
Get referred to Aadi Bioscience
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 4, 2025 PIPE closed for roughly $100 million, funding operations into 2028.
- April 2026 AACR data showed regressions and favorable tolerability across HWK-007, HWK-016, HWK-206.
- Whitehawk advanced HWK-007 and HWK-016 into Phase 1 and planned HWK-206 IND mid-2026.
What critics are saying
- FYARRO divestiture stripped the only commercial asset; Whitehawk now depends entirely on unproven ADCs.
- August 2024 PRECISION1 failure halted nab-sirolimus expansion and exposed weak clinical execution.
- Bispecific ADC ambitions still need INDs and Phase 1 data; a 2027 miss destroys the thesis.
What makes Aadi Bioscience unique
- March 2025 rebrand to Whitehawk Therapeutics sold FYARRO and reset Aadi around ADCs.
- Whitehawk licensed three preclinical ADCs from WuXi Biologics and Hangzhou DAC in December 2024.
- David Dornan joined as CSO, bringing deep ADC discovery and development experience.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$443.9M
Above
Industry Average
Funded Over
6 Rounds
Stock Price
Growth & Insights and Company News
6 month growth
↓ -12%1 year growth
↓ -12%2 year growth
↑ 14%Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gro
Whitehawk Therapeutics CEO Dave Lennon outlined the company's antibody-drug conjugate strategy at an annual healthcare conference, highlighting three clinical programmes and a cash runway into 2028. The company launched in 2025 after in-licensing a three-asset ADC portfolio from WuXi Biologics, with approximately $160 million in cash at the end of the prior year's third quarter. Whitehawk is developing next-generation ADCs using high-affinity targeting with attenuated-Fc design, paired-chain carbon-bonded bioconjugation and a proprietary Topo-1 payload. The company reports nonclinical advantages of 3-10 times greater tumour potency and 5-25 times improved stability versus average Topo-1 ADCs. Two programmes, HWK-007 and HWK-016, are enrolling in phase I dose-escalation studies. HWK-206 is expected to file an IND by mid-year, with clinical readouts anticipated in the first half of 2027.
MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.About Aadi BioscienceAadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers.Contact:[email protected]SOURCE Aadi Bioscience
To support these endeavors, Aadi has secured approximately $100 million in private investment in public equity (PIPE) financing, led by Ally Bridge Group, which is expected to close in the first half of 2025.
Aadi Bioscience stockholders approved key proposals at a Special Meeting, including the divestiture of its FYARRO Business to KAKEN INVESTMENTS INC., a PIPE financing involving the issuance of 21,592,000 shares at $2.40 each and pre-funded warrants for 20,076,500 shares at $2.40, and an amendment to increase shares under the 2021 Equity Plan by 6.3 million. A non-binding advisory vote on executive compensation related to the divestiture was also approved.
There are no jobs for Aadi Bioscience right now.
Find jobs on Simplify and start your career today
About Aadi Bioscience
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Post IPO Equity
Headquarters
Los Angeles, California
Founded
2011
There are no jobs for Aadi Bioscience right now.
Find jobs on Simplify and start your career today